Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris is viewed favorably because deucrictibant has delivered compelling late-stage proof-of-concept in HAE, with CHAPTER-3 showing an 83% mean monthly attack-rate reduction overall and 87% in Type 1/2 patients, plus 46% of treated patients remaining attack free over 24 weeks. The 40 mg once-daily oral profile appears differentiated versus injectable peers, combining near-injectable efficacy with convenience and a relatively clean safety readout, including no treatment-related serious adverse events and only limited liver-enzyme signals to monitor. Financially, the company ended 2Q26 with $363M in cash, implying runway into 2028, while physician survey data suggest meaningful commercial upside as oral convenience and strong efficacy could support broad switching and a large HAE market opportunity.

Pharvaris is viewed negatively because its valuation depends on a narrow pipeline centered almost entirely on deucrictibant and hereditary angioedema, leaving the company exposed if the mechanism, oral format, or prophylaxis hypothesis fails to translate from positive Phase 2 signals into pivotal Phase 3 success. The commercial path is also challenging, as HAE already has several preventive and treatment options, including generics, so Pharvaris must prove clear differentiation while building U.S. and EU launch infrastructure it does not yet have. Financially, it is expected to continue net losses at least until commercialization and likely through the early launch phase, with a meaningful risk of additional capital raises and dilution if approval, safety, or uptake disappoints.